Navigation Links
Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
Date:9/28/2007

/p>

correction) to type IV (graft porosity, rarely seen with current

devices). In the study, the occurrence of early endoleaks was low and

included 18 (5.5%) type I, four (1.2%) type II, and two (0.6%) type III

endoleaks.

-- Paraplegia: Thoracic ELG repair can cause decreased blood supply to the

spinal cord, leading to paraplegia. In this study, paraplegia occurred

in five (1.5%) patients and paresis (slight or partial paralysis) in

three (0.9%); two of the latter improved and one resolved completely

prior to discharge. Paraplegia remains low as a complication and

expectedly increases with difficult anatomy, specific conditions or

open surgical approach. Associated paraplegia with open repair is

estimated at 4%.

-- Mortality: At short-term follow-up, 18 (5.5%) deaths related to the

underlying thoracic aortic pathology occurred within the first thirty

days of the procedure, including three intraoperative deaths. Late

mortality was 9.6% with 31 deaths unrelated to the procedure or

underlying condition.

-- Complications: The overall complication rate was 22.7%, 14.2% (46) in

elective cases and 8.5% (28) in non-elective cases. The vast majority

of these were minor and easily managed with satisfactory outcomes.

Thoracic Aortic Aneurysms and Related Conditions

The aorta is the largest artery in the human body which carries blood away from the heart, with the thoracic aorta being the portion of the aorta coursing through the chest. When a weak area of the thoracic aorta expands or bulges like a balloon, it is called a thoracic aortic aneurysm (TAA). TAAs are often caused by atherosclerosis, or hardening and weakening of the arteries. An aortic dissection, which is often associated with high blood pressure, occurs when blood flow forces apart and weakens the aortic wall layers, often leading to ane
'/>"/>

SOURCE The Arizona Heart Institute
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
6. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
7. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
8. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 3Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 4Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 5Nplate(R) Data From MDS Studies Presented at ASH 2Nplate(R) Data From MDS Studies Presented at ASH 3Nplate(R) Data From MDS Studies Presented at ASH 4Nplate(R) Data From MDS Studies Presented at ASH 5Nplate(R) Data From MDS Studies Presented at ASH 6Nplate(R) Data From MDS Studies Presented at ASH 7Nplate(R) Data From MDS Studies Presented at ASH 8Nplate(R) Data From MDS Studies Presented at ASH 9Nplate(R) Data From MDS Studies Presented at ASH 10Florida Gentle Dental Dentists Giving Away Smile Makeover and Orthodontic Braces at 7th Annual Our Kids World Family Fun Festival 54944 1Florida Gentle Dental Dentists Giving Away Smile Makeover and Orthodontic Braces at 7th Annual Our Kids World Family Fun Festival 54944 2Florida Gentle Dental Dentists Giving Away Smile Makeover and Orthodontic Braces at 7th Annual Our Kids World Family Fun Festival 54944 3Mantaro Partners with Sparsense to Deliver High Performance Digital Image and Signal Processing Solutions 54940 1Mantaro Partners with Sparsense to Deliver High Performance Digital Image and Signal Processing Solutions 54940 2Mantaro Partners with Sparsense to Deliver High Performance Digital Image and Signal Processing Solutions 54940 3Increased climate volatility expected to worsen poverty vulnerability in developing countries 9633 1Increased climate volatility expected to worsen poverty vulnerability in developing countries 9633 2